跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/ACTRN12618001047280
ACTRN12618001047280已完成2 期

A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of BTX 1503 in Patients with Moderate to Severe Acne Vulgaris

Botanix Pharmaceuticals Ltd0 个研究点目标入组 386 人开始时间: 2018年6月22日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
2 期
状态
已完成
入组人数
386
研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
12 Years 至 40 Years（—）
性别
All

入选标准

  • •To be included in the study, subjects with acne vulgaris must meet the following inclusion criteria.
  • •- Subject is of either gender and 12 to 40 years of age.
  • •- Subject is in good general health without clinically significant haematological, cardiac, respiratory, renal, endocrine, gastrointestinal, psychiatric, hepatic, or malignant disease, as determined by the investigator.
  • •- Subject is able and willing to complete the study and to comply with all study instructions and attend the necessary visits.
  • •-Subject has acne vulgaris of the face defined as:
  • •a. 20 to 50 (inclusive) inflammatory lesions on the face
  • •b. 20 to 100 (inclusive) non-inflammatory lesions on the face
  • •c. An Investigator Global Assessment (IGA) score for acne severity of 3 or 4 (moderate or severe) assessed on the face.
  • •-Subject has less than or <3 nodular/cystic acne lesions (>5 mm in diameter).
  • •-Subject must refrain from the use of other treatments for acne during the study.
  • •-Subject must agree to not wash or shave their face, swim or otherwise get their face wet for at least 1 hour after application of study medication.
  • •-Subject must agree to maintain their regular use of sunscreens, moisturizers, shaving cream, and facial make up throughout the entire course of the study.
  • •- Sexually active women of childbearing potential must use appropriate birth control methods.

排除标准

  • •-People who would otherwise qualify for the study but are living in the same household as a study subject, are not allowed to participate in the study.
  • •-Female subject who is breast feeding, pregnant, or planning to become pregnant any time during the course of the study.
  • •-Subject has acne conglobata, acne fulminans, secondary acne (chloracne), pseudo-folliculitis, severe acne requiring systemic treatment, or is taking a medication known to induce or exacerbate acne.
  • •-Subject has severe truncal acne.
  • •-Subject has excessive facial hair that would interfere with the evaluation of safety or with the diagnosis or assessment of acne vulgaris.
  • •-Subject has sunburns, unevenness in skin tones, tattoos, scars, excessive hair, freckles, birthmarks, moles, or other skin damage or abnormality that would result in the inability to evaluate the skin of the face.
  • •-Subject has any skin condition of the face other than acne vulgaris.
  • •-Subject has used oral retinoid (e.g. isotretinoin) within 6 months (180 days) prior to the
  • •-Subject has used Vitamin A supplements greater than 10,000 units/day within 6 months (180 days) prior to the Baseline Visit.
  • •-Subject has used androgen receptor blockers (such as spironolactone or flutamide) within 3 months (90 days) prior to the Baseline Visit.
  • •-Subject has initiated treatment with hormonal therapy or changed dosing with hormonal therapy within 3 months (90 days) prior to the Baseline Visit. Note: Dose and frequency of any hormonal therapy started more than 3 months (90 days) prior to the Baseline Visit must remain unchanged throughout the study. Hormonal therapies include, but are not limited to, anabolic steroids and birth control pills. Subjects taking testosterone therapy are excluded from participation.
  • •-Subject has had facial procedures (chemical or laser peel, microdermabrasion, etc.) within 8 weeks (56 days) prior to the Baseline Visit.
  • •-Subject has had treatment with systemic antibiotics within 4 weeks (28 days) prior to the Baseline Visit.
  • •-Subject has had treatment with systemic anti-acne drugs within 4 weeks (28 days) prior to the Baseline Visit.
  • •-Subject has had treatment with systemic anti-inflammatory drugs within 4 weeks (28 days) prior to the Baseline Visit.
  • •Note: Occasional non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin use on an as-needed basis, and if not used consecutively for >14 days prior to the Baseline Visit, is acceptable and does not require washout. Subjects receiving intranasal and inhaled corticosteroids may participate. Low dose (81mg) aspirin taken daily is acceptable.
  • •-Subject has had treatment with systemic (oral) corticosteroids other immunosuppressive medications within 4 weeks (28 days) prior to the Baseline Visit.
  • •-Subject has had treatment with prescription topical retinoid use on the face (e.g. tretinoin, tazarotene) within 4 weeks (28 days) prior to the Baseline Visit.
  • •-Subject has had treatment with topical prescription antibiotics (e.g. dapsone, clindamycin, erythromycin, or sulfacetamide) or combination products that include a topical antibiotic within 2 weeks (14 days) prior to the Baseline Visit.
  • •-Subject has had treatment with over-the-counter (OTC) topical medications for the treatment of acne vulgaris including benzoyl peroxide, topical anti-inflammatory medications, corticosteroids, adapalene, a-hydroxy/glycolic acid on the face within 2 weeks (14 days) prior to the Baseline Visit.
  • •-Subject has had photodynamic therapy within 8 week

研究者

相似试验

进行中（未招募）
1 期
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIATardive Dyskinesia
EUCTR2014-001890-15-CZAuspex Pharmaceuticals, Inc.92
进行中（未招募）
1 期
EFFICACY AND LONG TERM SAFETY STUDY OF DUPILUMAB IN ADULTPATIENTS WITH MODERATE0-TO-SEVERE ATOPIC DERMATITIS.
EUCTR2013-003254-24-RORegeneron Pharmaceuticals, Inc.740
已完成
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PARALLEL GROUP TO DETERMINE IF, IN PATIENTS WITH TYPE 2 DIABETES WITH HIGH RISK OF CARDIOVASCULAR AND RENAL EVENTS, ALISKIREN, IN ADDITION TO CONVENTIONAL TREATMENT, REDUCES MORBIDITY AND CARDIOVASCULAR AND RENAL MORTALITY
PER-079-07OVARTIS BIOSCIENSES PERU S.A.,87
已完成
不适用
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY IN EUROPE / LATIN AMERICA, CANADA TO EVALUATE THE EFFECT OF TOLTERODINE FOR PROLONGED RELEASE ON NICTURIA IN PATIENTS WITH HYPERACTIVE BLADDER SYMPTOMS (VHA)
PER-047-02PHARMACIA & UPJOHN INTERAMERICAN CORPORATION,
进行中（未招募）
不适用
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 75 MG AND 150 MG DOSES OF ERB-041 ON THE REDUCTION OF SYMPTOMS ASSOCIATED WITH ENDOMETRIOSIS DURING TREATMENT AND POST TREATMENT IN REPRODUCTIVE-AGED WOME
EUCTR2006-000068-10-BEWyeth Research Division of Wyeth Pharmaceuticals Inc.150